サインイン 無料でサインアップします。

Beam TherapeuticsのEV / EBITDA

Beam TherapeuticsのEV / EBITDAは何ですか。

Beam Therapeutics Inc.のEV / EBITDAはN/Aです。

EV / EBITDAの定義は何ですか。



EV / EBITDA は、企業価値をEBITDA（利息、税金、減価償却費および償却費を控除する前の利益）で割ったものですです。これは、株価がどれほど高価で、P / E比よりも頻繁に企業をお互いを比較するために使用されます。これは、投資家が会社のキャッシュフローの利益のために支払う価格を測定します。

Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.

NASDAQのセクタHealth CareにおけるEV / EBITDAの企業と比べるBeam Therapeutics

Beam Therapeuticsは何をしますか。

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Beam Therapeuticsと類似のev / ebitda